BeiGene
BGNE
#984
Rank
C$28.59 B
Marketcap
$256.40
Share price
1.55%
Change (1 day)
5.01%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -C$1.18 Billion

According to BeiGene 's latest financial reports the company's current earnings are C$3.31 Billion. In 2023 the company made an earning of -C$1.73 Billion, an increase over its 2022 earnings that were of -C$2.57 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$1.18 Billion-32.22%
2023 -C$1.73 Billion-32.52%
2022 -C$2.57 Billion24.39%
2021 -C$2.07 Billion-13.21%
2020 -C$2.38 Billion72.69%
2019 -C$1.38 Billion36.01%
2018 -C$1.02 Billion616.83%
2017 -C$0.15 Billion-15.24%
2016 -C$0.17 Billion107.91%
2015 -C$80.01 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$26 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.17 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA